FDA warns of HORV risk with vancomycin intraocular injection

The FDA is warning against the use of prophylactic intraocular vancomycin formulations during cataract surgery because there is a risk for hemorrhagic occlusive retinal vasculitis.Hemorrhagic occlusive retinal vasculitis (HORV), a rare, potentially blinding postoperative complication, has been seen in dozens of patients who received intraocular injections of vancomycin formulations, according to an FDA Compounding Risk Alert.

Full Story →